VRTX today
$550.51+$3.48 (+0.64%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourBullish
1 hourBullish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns down below $484.08
Key levels
Resistance$568.67
Support$546.17
Support$527.38
Latest news & SEC filings
NewsEvotec pauses manufacturing for Vertex's povetacicept
NewsInsider at Vertex Pharmaceuticals signals plan to sell stock
All VRTX news →About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that develops medicines for serious diseases. Its approved products treat cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company sells primarily to specialty pharmacies, distributors, and hospitals, and it operates in the United States, Europe, Canada, Australia, and the Middle East.
Based on the company's 10-K filed Feb 13, 2026.
Nasdaq · Healthcare
VERTEX PHARMACEUTICALS INC / MA (VRTX)
What Is the Price Target for VRTX?
SEPT Low Target
$437.00
SEPT Mid Target
$622.50
SEPT High Target
$725.00
Analyst Consensus
$622.50
Is VRTX a Buy or Sell Right Now?
Thesis
- •Revenue growing 8.9% YoY with STABLE trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VRTX.
Start Free Trial →Is VRTX Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$506.40
46
Moat Score
NARROW
4/9
Piotroski Score
14.3
Altman Z-Score
What Is Smart Money Doing with VRTX?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
BUYING
3 buys / 4 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Kewalramani Reshma | director officer | Sale | 11,866 | $6.3M | Nov 6, 2026 |
| Brennan Daniel J. | director | Buy | 795 | $400K | Oct 20, 2026 |
| Ambrose Kristen | officer | Buy | 5,000 | - | Aug 28, 2026 |
| SACHS BRUCE I | director | Sale | 6,000 | - | Aug 27, 2026 |
| Tatsis Ourania | officer | Buy | 8,251 | - | Jul 21, 2026 |
| Sachdev Amit | officer | Buy | 8,251 | - | Jul 21, 2026 |
| Bozic Carmen | officer | Sale | 596 | $288K | Jun 26, 2026 |
| Bozic Carmen | officer | Sale | 1,745 | $785K | Jun 5, 2026 |
| Liu Joy | officer | Sale | 828 | $364K | Jun 1, 2026 |
| Bozic Carmen | officer | Sale | 1,974 | $888K | May 29, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →VRTX Growth Story
Revenue YoY
8.9%
3yr Revenue CAGR
10.3%
EPS Growth YoY
836.54%
FCF Growth YoY
504.1%
Revenue Trend
STABLE
Dark Pool Trades for VRTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for VRTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:52 | $547.03 | 38,160 | $$20.9M | BUY |
| 22:25:08 | $547.03 | 11,833 | $$6.5M | BUY |
| 21:57:56 | $547.03 | 2,423 | $$1.3M | BUY |
| 21:28:26 | $547.03 | 3,942 | $$2.2M | BUY |
| 21:03:26 | $547.03 | 31,213 | $$17.1M | BUY |
5 dark pool trades shown · $$47.9M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for VRTX
PREVIEWSEPT Investing provides real-time options flow tracking for VRTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $540 | Nov 20 | 9 | $$2614 | 2 | SWEEP |
| PUT | $540 | Nov 20 | 9 | $$1315 | 1 | SWEEP |
| PUT | $520 | Dec 18 | 37 | $$1525 | 1 | SWEEP |
| PUT | $520 | Dec 18 | 37 | $$3050 | 2 | SWEEP |
| PUT | $540 | Nov 20 | 9 | $$2630 | 2 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About VRTX
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for VRTX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $VRTX -- Bullish VRTX breakout at $513.79. Day range $496.72-$514.25. Last candle: strong bullish close (98% buying). Holds while above $507.92. The Play: Three scenarios from here: Ho...
Zone Setup -- $VRTX (VERTEX PHARMACEUTICALS INC / MA) Price: $499.65 | Zone: $482.20 to $503.89 Conviction: HIGH | Analyst upside: +14.4% Near resistance (80% of range) — breakout watch. Earnings: E...
Join 3,500+ traders discussing VRTX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for VERTEX PHARMACEUTICALS INC / MA (VRTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →VRTX — frequently asked questions
What is VRTX stock price today?
VERTEX PHARMACEUTICALS INC / MA (VRTX) is at $550.51, up 0.64% (+$3.48) at the Nov 12, 2026 close.
Why is VRTX stock moving today?
Latest VRTX news — Nov 9, 2026: Evotec pauses manufacturing for Vertex's povetacicept · Nov 6, 2026: Insider at Vertex Pharmaceuticals signals plan to sell stock
Why did VRTX stock move on Nov 2, 2026?
Vertex Pharmaceuticals reported Q3 2026 adjusted EPS of $4.76, missing the $4.82 estimate, while revenue of $3.441 billion beat the $3.417 billion estimate. The company also raised its full-year 2026 sales guidance to $13.150B-$13.250B from $13.100B-$13.200B, though the new midpoint is slightly below the $13.245B consensus.
What is the VRTX price target?
The average analyst price target for VRTX is $622.50, ranging from $437 to $725, based on 14 analysts. Latest: Barclays raises on Nov 4, 2026.
What do analysts rate VRTX?
Analyst ratings for VRTX: 0 Buy, 24 Hold, 0 Sell — consensus Hold.
Did VRTX beat earnings?
VRTX last reported on Nov 2, 2026: EPS $4.76 vs $4.82 expected — a miss of 1.2%.
What is VRTX's P/E ratio?
VRTX trades at a P/E of 34.9 vs a Healthcare average of 17.9.
Does VRTX pay a dividend?
VRTX does not currently pay a dividend.
What are VRTX support and resistance levels?
Support: $546.17, $527.38, $509.20. Resistance: $568.67.
What are insiders doing with VRTX?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on VRTX?
Nov 9, 2026: Evotec pauses manufacturing for Vertex's povetacicept · Nov 6, 2026: Insider at Vertex Pharmaceuticals signals plan to sell stock